市場調查報告書
商品編碼
1500527
穿戴式注射器市場:按類型、技術、應用、最終用途、分銷管道分類 - 2024-2030 年全球預測Wearable Injector Market by Type (Body Worn Patch Injector, Off Body Worn Patch Injector), Technology (Expanding Battery, Motor Driven, Rotary Pump), Application, End-Use, Distribution Channel - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年穿戴式注射器市場規模為78.4億美元,預計2024年將達到87.1億美元,2030年將達到165.6億美元,複合年成長率為11.26%。
穿戴式注射器是一種創新的醫療設備,旨在以比傳統注射器注射更方便、更安全、更少痛苦的方式向患者皮下注射大劑量藥物。這些設備緊密貼合患者的身體,具有移動性和靈活性,同時在預設時間內輸送大量黏性藥物。穿戴式針筒已成為治療糖尿病、癌症、心血管疾病和自體免疫疾病等慢性疾病的突破性藥物傳遞方法。穿戴式注射器的採用主要是由於需要持續用藥的慢性疾病(例如糖尿病和自體免疫疾病)盛行率的上升所推動的。穿戴式注射器的便利性和效率,加上病人對自我給藥的偏好,正在支持穿戴式注射器市場的擴張。然而,穿戴式注射器市場面臨一些挑戰,包括高昂的開發和製造成本以及需要各個地區的監管合規和核准,這些都減緩了新設備進入市場的速度。然而,對生技藥品的需求不斷成長,通常需要穿戴式注射器提供的精確劑量和持續釋放機制,正在開闢新的成長途徑。遠端醫療和遠端患者監護的趨勢正在創造對具有連接功能的先進穿戴式注射器的需求。
主要市場統計 | |
---|---|
基準年[2023] | 78.4億美元 |
預測年份 [2024] | 87.1億美元 |
預測年份 [2030] | 165.6億美元 |
複合年成長率(%) | 11.26% |
區域洞察
美洲穿戴式注射器市場的特點是先進的醫療基礎設施和高醫療支出。糖尿病和心血管疾病等慢性病的盛行率不斷上升,以及對生技藥品的高需求正在推動穿戴式注射器在該地區的採用。對醫療設備的監管支援也在穿戴式注射器的快速核准和商業化中發揮關鍵作用。歐洲擁有強大的醫療保健系統、不斷上升的醫療成本以及對先進治療設備的高度認知,因此穿戴式注射器的採用率正在增加。同時,在醫療基礎設施改善、政府措施力度加大以及慢性病發病率上升的推動下,中東和非洲地區的市場正在逐漸擴大。由於醫療保健基礎設施的快速改善、可支配收入的增加以及對先進治療方法的認知不斷增強,預計亞太地區將成為穿戴式注射器市場成長最快的地區。在技術進步和政府支持政策的推動下,中國、日本和韓國處於穿戴式注射器採用的前沿。該地區龐大的人口基數,加上慢性病盛行率的不斷上升,為市場擴張提供了巨大的機會。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在穿戴式注射器市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對穿戴式注射器市場供應商的當前狀態進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對穿戴式注射器市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[198 Pages Report] The Wearable Injector Market size was estimated at USD 7.84 billion in 2023 and expected to reach USD 8.71 billion in 2024, at a CAGR 11.26% to reach USD 16.56 billion by 2030.
Wearable injectors are innovative medical devices designed to deliver large volumes of drugs subcutaneously to patients in a convenient, safe, and less painful way compared to traditional syringe-based injections. These devices adhere to the patient's body, allowing for mobility and flexibility while administering viscous, high-volume drugs over a predefined time period. Wearable injectors have emerged as a breakthrough in the administration of drugs for chronic diseases such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders. The adoption of wearable injectors is primarily propelled by the rising prevalence of chronic diseases that require continuous medication, such as diabetes and autoimmune diseases. The convenience and efficiency of wearable injectors, coupled with patient preference for self-administration, support the wearable injectors market expansion. Despite the progressive momentum, the wearable injectors market faces several challenges owing to the high cost associated with the development and manufacturing of these devices and the requirement for regulatory compliance and approval across different regions, which can prolong market entry for new devices. However, increasing demand for biologics, which often require precise dosing and slow release mechanisms provided by wearable injectors, opens new avenues for growth. The trend towards telehealth and remote patient monitoring creates demand for advanced wearable injectors with connectivity features.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 7.84 billion |
Estimated Year [2024] | USD 8.71 billion |
Forecast Year [2030] | USD 16.56 billion |
CAGR (%) | 11.26% |
Regional Insights
The wearable injectors market in the Americas is characterized by advanced healthcare infrastructure and high healthcare expenditure. The increasing prevalence of chronic diseases such as diabetes and cardiovascular diseases, coupled with a high demand for biologics, drives the adoption of wearable injectors in the region. Regulatory support for medical devices also plays a vital role in the rapid approval and commercialization of wearable injectors. Europe, with its robust healthcare systems, increased healthcare spending, and high awareness regarding advanced therapeutic devices, demonstrates higher adoption of wearable injectors. The market in the Middle East and Africa, however, is gradually growing, fueled by improving healthcare infrastructure, increasing government initiatives, and rising chronic disease prevalence. The APAC region is anticipated to witness the fastest growth in the wearable injectors market owing to its rapidly improving healthcare infrastructure, increasing disposable income, and growing awareness of advanced treatment methods. China, Japan, and South Korea are at the forefront of the adoption of wearable injectors, driven by technological advancements and supportive government policies. The region's vast population base, coupled with an increasing prevalence of chronic conditions, presents a significant opportunity for market expansion.
Market Insights
The market dynamics represent an ever-changing landscape of the Wearable Injector Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Wearable Injector Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Wearable Injector Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Approves Enable Injections' Wearable Injector
Enable Injections has announced the FDA approval of its Empaveli Injector, a wearable device revolutionizing the administration of subcutaneous therapy. Designed specifically for adults with paroxysmal nocturnal hemoglobinuria, the Empaveli Injector simplifies the treatment process by enabling hands-free delivery of up to 25 mL of medication, suitable for both home and clinical settings. With this advancement, Enable Injections aims to enhance patient care and also extend its reach through additional enFuse partnerships, ultimately elevating patient support on a global scale. [Published On: 2023-10-02]
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
Viridian Therapeutics, Inc., a biotechnology entity dedicated to crafting leading-edge treatments for grave and rare conditions, has collaborated with Enable Injections. This union aims to employ Enable's enFuse wearable drug delivery system, capable of administering up to 25mL, to improve patient care. This collaboration focuses on enhancing drug delivery convenience outside the scope of Viridian's Thyroid Eye Disease (TED) ventures, showing a deep commitment to patient-centered innovation. [Published On: 2023-05-08]
LTS Acquires Sorrel Wearable Injection Device Business
LTS Lohmann, a pharmaceutical technology company, has acquired the Sorrel wearable injector business from Eitan Medical Ltd., based in Netanya, Israel. This acquisition marks a significant leap for LTS, expanding its range of drug delivery solutions to include Sorrel's advanced large-volume wearable injector technologies, which are pivotal for the administration of large molecules and biologics. [Published On: 2023-04-21]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Wearable Injector Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Wearable Injector Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Becton, Dickinson and Company, CCBio, CeQur Corporation, DCA Design International Ltd, Debiotech SA, E3D Elcam Drug Delivery Devices, Enable Injections, Inc., EOFlow Co., Ltd., Gerresheimer AG, Insulet Corporation, LTS Lohmann Therapie-Systeme AG, Medtrum Technologies Inc., Neuma LLC by Kymanox Corporation, Noble International LLC by AptarGroup, Inc., NOVO Engineering, Shaily Engineering Plastics Ltd., SONCEBOZ SA, Stevanato Group S.p.A., Subcuject ApS, Viant, West Pharmaceutical Services, Inc., Ypsomed Holding AG, and ZwickRoell GmbH & Co. KG.
Market Segmentation & Coverage